INTEGUMENT-INFANT showed 49.1% achieving vIGA-AD clear/almost clear at week 4 and 27.3% meeting vIGA-AD Success, alongside rapid pruritus improvement.
Indication expansion addresses a major pediatric gap where topical corticosteroids are commonly used off-label yet constrained by sensitive-site and long-term continuous-use limitations.
Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis.
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2.
Once-daily, steroid-free roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis